I. Margarit

发表

Cumulative stabilizing effects of hydrophobic interactions on the surface of the neutral protease from Bacillus subtilis.

F. Frigerio, I. Margarit, R. Nogarotto, 1996, Protein engineering.

Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen

H. Tettelin, R. Rappuoli, D. Kasper, 2005, Science.

Surfome Analysis as a Fast Track to Vaccine Discovery

I. Margarit, G. Grandi, R. D'Aurizio, 2009, Molecular & Cellular Proteomics.

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.

G. Bensi, I. Margarit, E. Frigimelica, 2017, Vaccine.

Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic Streptococci and Enterococci.

I. Margarit, B. Kreikemeyer, S. Hammerschmidt, 2011, International journal of medical microbiology : IJMM.

The ancillary protein 1 of Streptococcus pyogenes FCT-1 pili mediates cell adhesion and biofilm formation through heterophilic as well as homophilic interactions

I. Margarit, G. Grandi, Scilla Buccato, 2012, Molecular microbiology.

Retaining the structural integrity of disulfide bonds in diphtheria toxoid carrier protein is crucial for the effectiveness of glycoconjugate vaccine candidates

I. Margarit, D. Veggi, R. Adamo, 2022, Chemical science.

Structure‐Guided Design of a Group B Streptococcus Type III Synthetic Glycan–Conjugate Vaccine

J. Jiménez-Barbero, I. Margarit, R. Adamo, 2020, Chemistry.

Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide

R. Rappuoli, I. Margarit, E. Malito, 2017, Proceedings of the National Academy of Sciences.

Analysis of Two-Component Systems in Group B Streptococcus Shows That RgfAC and the Novel FspSR Modulate Virulence and Bacterial Fitness

I. Margarit, G. Grandi, K. Doran, 2014, mBio.

Conserved anchorless surface proteins as group A streptococcal vaccine candidates

V. Nizet, B. Kobe, I. Margarit, 2012, Journal of Molecular Medicine.

The Streptococcus agalactiae complement interfering protein combines multiple complement-inhibitory mechanisms by interacting with both C4 and C3 ligands

I. Margarit, N. Norais, D. Donnarumma, 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Serotype IV Streptococcus agalactiae ST-452 has arisen from large genomic recombination events between CC23 and the hypervirulent CC17 lineages

C. Donati, I. Margarit, C. D. Rinaudo, 2016, Scientific Reports.

Structure of the Type IX Group B Streptococcus Capsular Polysaccharide and Its Evolutionary Relationship with Types V and VII

I. Margarit, G. Grandi, C. Toniolo, 2014, The Journal of Biological Chemistry.

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm.

I. Margarit, G. Grandi, C. Galeotti, 2009, The Journal of infectious diseases.

Scavenger receptor gp340 aggregates group A streptococci by binding pili

G. Bensi, I. Margarit, G. Grandi, 2008, Molecular microbiology.

Environmental Acidification Drives S. pyogenes Pilus Expression and Microcolony Formation on Epithelial Cells in a FCT-Dependent Manner

I. Margarit, G. Grandi, B. Kreikemeyer, 2010, PloS one.

Genomic Analysis Reveals Multi-Drug Resistance Clusters in Group B Streptococcus CC17 Hypervirulent Isolates Causing Neonatal Invasive Disease in Southern Mainland China

I. Margarit, C. D. Rinaudo, R. Rosini, 2016, Front. Microbiol..

Structure and Assembly of Group B Streptococcus Pilus 2b Backbone Protein

M. Bottomley, I. Margarit, E. Malito, 2015, PloS one.

Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.

I. Margarit, R. Adamo, M. Allan, 2015, Bioconjugate chemistry.

Acidic pH Strongly Enhances In Vitro Biofilm Formation by a Subset of Hypervirulent ST-17 Streptococcus agalactiae Strains

I. Margarit, D. Maione, J. Telford, 2014, Applied and Environmental Microbiology.

Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen

O. Jousson, G. Bensi, I. Margarit, 2014, Journal of extracellular vesicles.

Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease.

I. Margarit, G. Grandi, D. Maione, 2006, The Journal of infectious diseases.

Group B Streptococcus chimeric capsular polysaccharides as novel multivalent vaccine candidates

I. Margarit, R. Rosini, A. Spagnuolo, 2021, Glycoconjugate Journal.

Immune Response to Invasive Group B Streptococcus Disease in Adults

I. Margarit, E. Bartolini, C. D. Rinaudo, 2016, Emerging infectious diseases.

The Group B Streptococcus–Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways

I. Margarit, R. Rosini, Scilla Buccato, 2016, The Journal of Immunology.

Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination

I. Margarit, D. Maione, R. Berner, 2015, Expert review of anti-infective therapy.

Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.

I. Margarit, Francesca Zerbini, L. Morelli, 2015, ACS chemical biology.

Complement Pathways Deposition via the Lectin and Classical CIP Interacts with C 4 , Preventing C 3 b Secreted Protein − Streptococcus

I. Margarit, R. Rosini, Scilla Buccato, 2015 .

Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry.

I. Margarit, R. Adamo, Huili Zhai, 2014, Bioconjugate chemistry.

Preventing Newborn Infection with Maternal Immunization

R. Rappuoli, S. Black, I. Margarit, 2013, Science Translational Medicine.

Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST-17 strain

I. Margarit, K. Doran, C. D. Rinaudo, 2017, BMC Microbiology.

Biofilm formation by Streptococcus agalactiae: influence of environmental conditions and implicated virulence factors

I. Margarit, R. Rosini, 2015, Front. Cell. Infect. Microbiol..

Typing of the pilus-protein-encoding FCT region and biofilm formation as novel parameters in epidemiological investigations of Streptococcus pyogenes isolates from various infection sites.

I. Margarit, G. Grandi, B. Kreikemeyer, 2010, Journal of medical microbiology.

GBS type III oligosaccharides containing a minimal protective epitope can be turned into effective vaccines by multivalent presentation.

I. Margarit, R. Adamo, B. Brogioni, 2019, The Journal of infectious diseases.

Novel Multiplex Immunoassays for Quantification of IgG against Group B Streptococcus Capsular Polysaccharides in Human Sera

I. Margarit, M. Giuliani, M. Stella, 2019, mSphere.

Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women.

R. Devlieger, I. Margarit, G. Grandi, 2018, The Journal of infection.

A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.

I. Margarit, G. Grandi, M. Giuliani, 2012, Journal of immunological methods.

Streptococcus pyogenes: Basic Biology to Clinical Manifestations: Current Approaches to Group A Streptococcal Vaccine Development.

Manisha Pandey, I. Margarit, G. Grandi, 2016 .

Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial

I. Margarit, G. Leroux-Roels, B. Corsaro, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Estimating the burden of invasive Group B Streptococcal disease in young infants in southern mainland China: an observational study.

I. Margarit, C. D. Rinaudo, Wenjing Ji, 2015, International journal of clinical and experimental medicine.

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.

K. Edwards, I. Margarit, R. Beigi, 2020, Vaccine.

FHUSPA2/10 is a bactericidal monoclonal antibody targeting multiple repeated sequences of Moraxella catarrhalis UspA2.

I. Margarit, I. Ferlenghi, M. Scarselli, 2022, Vaccine.

Emergence and Global Dissemination of Host-Specific Streptococcus agalactiae Clones

I. Margarit, M. Kilian, K. Poulsen, 2010, mBio.

Manipulation of the DNA coding for the desulphurizing activity in a new isolate of Arthrobacter sp.

I. Margarit, F. de Ferra, L. Serbolisca, 1999, Applied Microbiology and Biotechnology.

Pili in Gram-positive pathogens

Rino Rappuoli, Guido Grandi, John L. Telford, 2006, Nature Reviews Microbiology.

Genome Analysis Reveals Pili in Group B Streptococcus

R. Rappuoli, I. Margarit, G. Grandi, 2005, Science.

Neonatal corticosterone mitigates autoimmune neuropsychiatric disorders associated with streptococcus in mice

J. Glennon, V. Roessner, I. Margarit, 2018, Scientific Reports.

Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case

J. Musser, G. Bensi, I. Margarit, 2012, Molecular & Cellular Proteomics.

Dissecting the Human Response to Staphylococcus aureus Systemic Infections

I. Margarit, E. Bartolini, F. Bagnoli, 2021, Frontiers in Immunology.

Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study

I. Margarit, D. Maione, J. Telford, 2022, Infection.

Effect of Glu-143 and His-231 substitutions on the catalytic activity and secretion of Bacillus subtilis neutral protease.

M. Zamai, I. Margarit, G. Grandi, 1989, Protein engineering.

Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation

J. Musser, G. Bensi, E. Graviss, 2007, Molecular microbiology.

Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline

C. Buchrieser, J. Parkhill, M. Davies, 2014, Nature Communications.

Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae

Ian T. Paulsen, Jonathan A. Eisen, Scott Peterson, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The Human Pathogen Streptococcus pyogenes Releases Lipoproteins as Lipoprotein-rich Membrane Vesicles*

R. Rappuoli, I. Margarit, G. Grandi, 2015, Molecular & Cellular Proteomics.

Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate.

R. Rappuoli, G. Bensi, I. Margarit, 2010, Vaccine.

SpyAD, a Moonlighting Protein of Group A Streptococcus Contributing to Bacterial Division and Host Cell Adhesion

G. Bensi, I. Margarit, G. Grandi, 2014, Infection and Immunity.

European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents

P. Paschou, V. Roessner, D. Martino, 2018, European Child & Adolescent Psychiatry.

Genomic Analysis Reveals the Molecular Basis for Capsule Loss in the Group B Streptococcus Population

H. Tettelin, C. Donati, I. Margarit, 2015, PloS one.

Cumulative stabilizing effects of glycine to alanine substitutions in Bacillus subtilis neutral protease.

F. Frigerio, I. Margarit, V. De Filippis, 1992, Protein engineering.

A study of HLA class II antigens in an Italian paediatric population with coeliac disease.

M. Mazzilli, I. Margarit, M. Bonamico, 1988, Disease markers.

Mice repeatedly exposed to Group-A β-Haemolytic Streptococcus show perseverative behaviors, impaired sensorimotor gating, and immune activation in rostral diencephalon

I. Margarit, R. Canese, E. Bartolini, 2015, Scientific Reports.

Identification of novel genomic islands coding for antigenic pilus‐like structures in Streptococcus agalactiae

I. Margarit, G. Grandi, M. Soriani, 2006, Molecular microbiology.

Protein Array Profiling of Tic Patient Sera Reveals a Broad Range and Enhanced Immune Response against Group A Streptococcus Antigens

J. Musser, G. Bensi, I. Margarit, 2009, PloS one.

Streptococcus pyogenes SpyCEP Influences Host-Pathogen Interactions during Infection in a Murine Air Pouch Model

I. Margarit, G. Grandi, D. Serruto, 2012, PloS one.

Capturing host‐pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP

I. Margarit, G. Grandi, R. Grifantini, 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Grafting of a calcium-binding loop of thermolysin to Bacillus subtilis neutral protease.

M Bolognesi, M. Bolognesi, I. Margarit, 1991, Biochemistry.

Corrigendum: Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline

C. Buchrieser, J. Parkhill, M. Davies, 2015, Nature Communications.

Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models

G. Bensi, I. Margarit, G. Grandi, 2018, Scientific Reports.

The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.

I. Margarit, G. Grandi, D. Maione, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from Streptococcus pyogenes

F. Mancini, G. Bensi, M. Bottomley, 2020, Computational and structural biotechnology journal.

Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes.

J. Musser, I. Margarit, G. Grandi, 2008, The Journal of infectious diseases.

Targeted Amino Acid Substitutions Impair Streptolysin O Toxicity and Group A Streptococcus Virulence

G. Bensi, I. Margarit, G. Grandi, 2013, mBio.

Transcriptional and Proteomic Profiles of Group B Streptococcus Type V Reveal Potential Adherence Proteins Associated with High-Level Invasion

S. Gygi, Lei Hua, I. Margarit, 2007, Infection and Immunity.

Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST-17 strain

I. Margarit, K. Doran, C. D. Rinaudo, 2017, BMC Microbiology.

Noncanonical sortase‐mediated assembly of pilus type 2b in group B Streptococcus

M. D'Onofrio, I. Margarit, E. Malito, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort

P. Paschou, V. Roessner, D. Martino, 2019, Brain, Behavior, and Immunity.

Structural alterations in mutant precursors of the yeast tRNALeu3 gene which behave as defective substrates for a highly purified splicing endoribonuclease.

G. Tocchini-Valentini, I. Margarit, D. Attardi, 1985, The EMBO journal.

Streptococcus pyogenes SpyCEP: a chemokine‐inactivating protease with unique structural and biochemical features

I. Margarit, G. Grandi, M. Mariani, 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.